Population pharmacokinetics and pharmacodynamic target attainment of meropenem in critically ill young children

Journal of Pediatric Pharmacology and Therapeutics

Volumn 22, Issue 4, 2017, Pages 276-285

  Cies, Jeffrey J ^a,b,c   Moore, Wayne S ^a   Enache, Adela ^d   Chopra, Arun ^e,f  

^a The Center for Pediatric Pharmacotherapy   (United States)

^b ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d Atlantic Diagnostic Laboratories LLC   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic dosage; Carbapenem; Meropenem; Pediatric; Pharmacodynamics; Pharmacokinetics; Pseudomonas aeruginosa

Indexed keywords

EID: 85040974171     PISSN: 15516776     EISSN: 2331348X     Source Type: Journal    
DOI: 10.5863/1551-6776-22.4.276     Document Type: Article

References (45)

1. Balamuth F, Weiss SL, Neuman MI, et al. Pediatric severe sepsis in U.S. children’s hospitals. Pediatr Crit Care Med. 2014;15(9):798-805.
2. Weiss SL, Fitzgerald JC, Pappachan J, et al. Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. Am J Respir Crit Care Med. 2015;191(10):1147-1157.
3. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157-1167.
4. Carcillo JA, Doughty L, Kofos D, et al. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med. 2003;29(6):980-984.
5. Cies JJ, Moore WS Jr, Calaman S, et al. Pharmacokinetics of continuous-infusion meropenem for the treatment of Serratia marcescens ventriculitis in a pediatric patient. Pharmacotherapy. 2015;35(4):e32-e36.
6. Cies JJ, Moore WS Jr, Conley SB, et al. Pharmacokinetics of continuous infusion meropenem with concurrent extracorporeal life support and continuous renal replacement therapy: a case report. J Pediatr Pharmacol Ther. 2016;21(1):92-97.
7. Cies JJ, Moore WS Jr, Dickerman MJ, et al. Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support. Pharmacotherapy. 2014;34(10):e175-e179.
8. Cies JJ, Moore WS Jr, Miller K, et al. Therapeutic drug monitoring of continuous-infusion acylovir for disseminated herpes simplex virus infection in a neonate receiving concurrent extracorporeal life support and continuous renal replacement therapy. Pharmacotherapy. 2015;35(2):229-233.
9. Cies JJ, Shankar V, Schlichting C, et al. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children. Pediatr Infect Dis J. 2014;33(2):168-173.
10. Ince I, de Wildt SN, Peeters MY, et al. Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years. Ther Drug Monit. 2012;34(4):381-389.
11. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet. 2006;45(8):755-773.
12. Roberts JA, Roberts MS, Robertson TA, et al. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration? Crit Care Med. 2009;37(3):926-933.
13. Smith BS, Yogaratnam D, Levasseur-Franklin KE, et al. Introduction to drug pharmacokinetics in the critically ill patient. Chest. 2012;141(5):1327-1336.
14. Joukhadar C, Frossard M, Mayer BX, et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med. 2001;29(2):385-391.
15. Meropenem [package insert]. Wilmington, DE: Aztra Zeneca Pharmaceuticals LP.
16. Ellis JM, Kuti JL, Nicolau DP. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program. Clin Ther. 2005;27(11):1820-1830.
17. De Cock PA, Standing JF, Barker CI, et al. Augmented renal clearance implies a need for increased amoxicillin-clavulanic acid dosing in critically ill children. Antimicrob Agents Chemother. 2015;59(11):7027-7035.
18. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637.
19. Neely MN, van Guilder MG, Yamada WM, et al. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012;34(4):467-476.
20. Yamaoka K, Nakagawa T, Uno T. Application of Akaike’’s information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978;6(2):165-175.
21. Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013;102(9):2941-2952.
22. Meibohm B, Laer S, Panetta JC, et al. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. 2005;7(2):E475-E487.
23. DeRyke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy. 2007;27(3):333-342.
24. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009;4(11):1832-1843.
25. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998;27(1):10-22.
26. Ariano RE, Nyhlen A, Donnelly JP, et al. Pharmacokinetics and pharmacodynamics of meropenem in febrile neu-tropenic patients with bacteremia. Ann Pharmacother. 2005;39(1):32-38.
27. Lexi-Comp Online. Lexi-Comp Inc. Accessed March 19, 2017.
28. Pediatric & neonatal lexi-drugs online. Lexi-Comp, Inc. Accessed March 19, 2017.
29. Thomson Micromedex Web site. http://uspdi.micromedex. com/. Accessed March 19, 2017.
30. Blumer JL, Reed MD, Kearns GL, et al. Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children. Antimicrob Agents Chemother. 1995;39(8):1721-1725.
31. Du X, Li C, Kuti JL, et al. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients. J Clin Pharmacol. 2006;46(1):69-75.
32. Parker EM, Hutchison M, Blumer JL. The pharmacokinetics of meropenem in infants and children: a population analysis. J Antimicrob Chemother. 1995;36(suppl A):63-71.
33. Kongthavonsakul K, Lucksiri A, Eakanunkul S, et al. Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection. Int J Antimicrob Agents. 2016;48(2):151-157.
34. Cies JJ, Jain J, Kuti JL. Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia. Pediatr Blood Cancer. 2015;62(3):477-482.
35. Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16.
36. Udy AA, Varghese JM, Altukroni M, et al. Subthera-peutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest. 2012;142(1):30-39.
37. Weiss SL, Fitzgerald JC, Balamuth F, et al. Delayed antimicrobial therapy increases mortality and organ dysfunction duration in pediatric sepsis. Crit Care Med. 2014;42(11):2409-2417.
38. Muszynski JA, Knatz NL, Sargel CL, et al. Timing of correct parenteral antibiotic initiation and outcomes from severe bacterial community-acquired pneumonia in children. Pediatr Infect Dis J. 2011;30(4):295-301.
39. Amaker RD, DiPiro JT, Bhatia J. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 1996;40(5):1139-1142.
40. Bressolle F, Kinowski JM, de la Coussaye JE, et al. Clinical pharmacokinetics during continuous haemofiltration. Clin Pharmacokinet. 1994;26(6):457-471.
41. Courter JD, Kuti JL, Girotto JE, et al. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer. 2009;53(3):379-385.
42. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44(3):357-363.
43. Tam VH, Louie A, Lomaestro BM, et al. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy. 2003;23(3):291-295.
44. Goncalves-Pereira J, Povoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Crit Care. 2011;15(5):R206.
45. Beumier M, Casu GS, Hites M, et al. Elevated β-lactam concentrations associated with neurological deterioration in ICU septic patients. Minerva Anestesiol. 2015;81(5):497-506.